Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: A meta-analysis

Nonalcoholic fatty liver disease (NAFLD) is emerging as a public health issue worldwide and is highly prevalent in patients with type 2 diabetes mellitus (T2DM). However, there was a great disparity across studies in the estimated prevalence of NAFLD in T2DM patients. This meta-analysis, therefore,...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Medicine (Baltimore) 2017-09, Vol.96 (39), p.e8179-e8179
Hauptverfasser: Dai, Wenjie, Ye, Ling, Liu, Aizhong, Wen, Shi Wu, Deng, Jing, Wu, Xin, Lai, Zhiwei
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page e8179
container_issue 39
container_start_page e8179
container_title Medicine (Baltimore)
container_volume 96
creator Dai, Wenjie
Ye, Ling
Liu, Aizhong
Wen, Shi Wu
Deng, Jing
Wu, Xin
Lai, Zhiwei
description Nonalcoholic fatty liver disease (NAFLD) is emerging as a public health issue worldwide and is highly prevalent in patients with type 2 diabetes mellitus (T2DM). However, there was a great disparity across studies in the estimated prevalence of NAFLD in T2DM patients. This meta-analysis, therefore, aimed to estimate the pooled prevalence of NAFLD in T2DM patients. Electronic databases of PubMed, Web of Science, Embase, Chinese National Knowledge Infrastructure, and Wanfang were searched using MeSH terms to identify relevant studies. Eligibility assessment and data extraction were conducted independently by 2 investigators and a meta-analysis was performed to synthesize the data. Heterogeneity was evaluated using the Cochran Q test and quantified using the I statistic. Publication bias was assessed using both the Begg and Egger tests. Subgroup analyses were performed to identify the possible sources of heterogeneity. Twenty-four studies involving 35,599 T2DM patients were included in this meta-analysis, of which 20,264 were identified with NAFLD. A high degree of heterogeneity (I = 99.0%, P 
doi_str_mv 10.1097/MD.0000000000008179
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5626318</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1944437450</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4058-5a07ee6c4d66eb0d548d742be339f54aa9fe5166127954bff549e992f369126b3</originalsourceid><addsrcrecordid>eNpdkU1v1DAQhi0EokvhFyAhH7mk9bdjDkhVy0elVu0BzpaTTIjBGy-2s6v99xi2rVrm4tHMO8-M9SL0lpITSow-vb44IY-ipdo8QysquWqkUeI5WhHCZKONFkfoVc4_CaFcM_ESHbHWVJmWK-RvE2xdgLkHHEc8x9mFPk4x-B6PrpQ9Dn4LCQ8-g8uA_Yw3rniYS8Y7XyZc9hvArPZdBwUyXkMIviz5Az6reXGNq8R99vk1ejG6kOHN3XuMvn_-9O38a3N18-Xy_Oyq6QWRbSMd0QCqF4NS0JFBinbQgnXAuRmlcM6MIKlSlGkjRTfWmgFj2MiVoUx1_Bh9PHA3S7eGoa-nJhfsJvm1S3sbnbdPO7Of7I-4tVIxxWlbAe_vACn-XiAXu_a5r99yM8QlW2qEEFwLSaqUH6R9ijknGB_WUGL_mmSvL-z_JtWpd48vfJi5d6UKxEGwi6FAyr_CsoNkJ3ChTP94UhvWMEI1McyQplZUy_8AMNWeJg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1944437450</pqid></control><display><type>article</type><title>Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: A meta-analysis</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Wolters Kluwer Open Health</source><source>IngentaConnect Free/Open Access Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Dai, Wenjie ; Ye, Ling ; Liu, Aizhong ; Wen, Shi Wu ; Deng, Jing ; Wu, Xin ; Lai, Zhiwei</creator><creatorcontrib>Dai, Wenjie ; Ye, Ling ; Liu, Aizhong ; Wen, Shi Wu ; Deng, Jing ; Wu, Xin ; Lai, Zhiwei</creatorcontrib><description>Nonalcoholic fatty liver disease (NAFLD) is emerging as a public health issue worldwide and is highly prevalent in patients with type 2 diabetes mellitus (T2DM). However, there was a great disparity across studies in the estimated prevalence of NAFLD in T2DM patients. This meta-analysis, therefore, aimed to estimate the pooled prevalence of NAFLD in T2DM patients. Electronic databases of PubMed, Web of Science, Embase, Chinese National Knowledge Infrastructure, and Wanfang were searched using MeSH terms to identify relevant studies. Eligibility assessment and data extraction were conducted independently by 2 investigators and a meta-analysis was performed to synthesize the data. Heterogeneity was evaluated using the Cochran Q test and quantified using the I statistic. Publication bias was assessed using both the Begg and Egger tests. Subgroup analyses were performed to identify the possible sources of heterogeneity. Twenty-four studies involving 35,599 T2DM patients were included in this meta-analysis, of which 20,264 were identified with NAFLD. A high degree of heterogeneity (I = 99.0%, P &lt; .001) was observed among the eligible studies, with the reported prevalence ranging from 29.6% to 87.1%. The pooled prevalence of NAFLD in T2DM patients, by a random-effects model, was 59.67% (95% confidence interval: 54.31-64.92%). Sensitivity was low and both the Begg test and Egger test showed low possibility of publication bias. Subgroup analyses indicated that the prevalence of NAFLD in T2DM patients differed by gender, obesity, hypertension, dyslipidemia, coronary heart disease, and chronic kidney disease. The high pooled prevalence of NAFLD in T2DM patients found in this study significantly underscores the need for early assessment of NAFLD and the importance of strengthening the management of NAFLD in T2DM patients.</description><identifier>ISSN: 0025-7974</identifier><identifier>EISSN: 1536-5964</identifier><identifier>DOI: 10.1097/MD.0000000000008179</identifier><identifier>PMID: 28953675</identifier><language>eng</language><publisher>United States: The Authors. Published by Wolters Kluwer Health, Inc. All rights reserved</publisher><subject>Diabetes Mellitus, Type 2 - complications ; Disease Management ; Early Diagnosis ; Humans ; Needs Assessment ; Non-alcoholic Fatty Liver Disease - diagnosis ; Non-alcoholic Fatty Liver Disease - epidemiology ; Non-alcoholic Fatty Liver Disease - therapy ; Prevalence ; Systematic Review and Meta-Analysis</subject><ispartof>Medicine (Baltimore), 2017-09, Vol.96 (39), p.e8179-e8179</ispartof><rights>The Authors. Published by Wolters Kluwer Health, Inc. All rights reserved.</rights><rights>Copyright © 2017 the Author(s). Published by Wolters Kluwer Health, Inc. 2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4058-5a07ee6c4d66eb0d548d742be339f54aa9fe5166127954bff549e992f369126b3</citedby><cites>FETCH-LOGICAL-c4058-5a07ee6c4d66eb0d548d742be339f54aa9fe5166127954bff549e992f369126b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5626318/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5626318/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,27903,27904,53769,53771</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28953675$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dai, Wenjie</creatorcontrib><creatorcontrib>Ye, Ling</creatorcontrib><creatorcontrib>Liu, Aizhong</creatorcontrib><creatorcontrib>Wen, Shi Wu</creatorcontrib><creatorcontrib>Deng, Jing</creatorcontrib><creatorcontrib>Wu, Xin</creatorcontrib><creatorcontrib>Lai, Zhiwei</creatorcontrib><title>Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: A meta-analysis</title><title>Medicine (Baltimore)</title><addtitle>Medicine (Baltimore)</addtitle><description>Nonalcoholic fatty liver disease (NAFLD) is emerging as a public health issue worldwide and is highly prevalent in patients with type 2 diabetes mellitus (T2DM). However, there was a great disparity across studies in the estimated prevalence of NAFLD in T2DM patients. This meta-analysis, therefore, aimed to estimate the pooled prevalence of NAFLD in T2DM patients. Electronic databases of PubMed, Web of Science, Embase, Chinese National Knowledge Infrastructure, and Wanfang were searched using MeSH terms to identify relevant studies. Eligibility assessment and data extraction were conducted independently by 2 investigators and a meta-analysis was performed to synthesize the data. Heterogeneity was evaluated using the Cochran Q test and quantified using the I statistic. Publication bias was assessed using both the Begg and Egger tests. Subgroup analyses were performed to identify the possible sources of heterogeneity. Twenty-four studies involving 35,599 T2DM patients were included in this meta-analysis, of which 20,264 were identified with NAFLD. A high degree of heterogeneity (I = 99.0%, P &lt; .001) was observed among the eligible studies, with the reported prevalence ranging from 29.6% to 87.1%. The pooled prevalence of NAFLD in T2DM patients, by a random-effects model, was 59.67% (95% confidence interval: 54.31-64.92%). Sensitivity was low and both the Begg test and Egger test showed low possibility of publication bias. Subgroup analyses indicated that the prevalence of NAFLD in T2DM patients differed by gender, obesity, hypertension, dyslipidemia, coronary heart disease, and chronic kidney disease. The high pooled prevalence of NAFLD in T2DM patients found in this study significantly underscores the need for early assessment of NAFLD and the importance of strengthening the management of NAFLD in T2DM patients.</description><subject>Diabetes Mellitus, Type 2 - complications</subject><subject>Disease Management</subject><subject>Early Diagnosis</subject><subject>Humans</subject><subject>Needs Assessment</subject><subject>Non-alcoholic Fatty Liver Disease - diagnosis</subject><subject>Non-alcoholic Fatty Liver Disease - epidemiology</subject><subject>Non-alcoholic Fatty Liver Disease - therapy</subject><subject>Prevalence</subject><subject>Systematic Review and Meta-Analysis</subject><issn>0025-7974</issn><issn>1536-5964</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkU1v1DAQhi0EokvhFyAhH7mk9bdjDkhVy0elVu0BzpaTTIjBGy-2s6v99xi2rVrm4tHMO8-M9SL0lpITSow-vb44IY-ipdo8QysquWqkUeI5WhHCZKONFkfoVc4_CaFcM_ESHbHWVJmWK-RvE2xdgLkHHEc8x9mFPk4x-B6PrpQ9Dn4LCQ8-g8uA_Yw3rniYS8Y7XyZc9hvArPZdBwUyXkMIviz5Az6reXGNq8R99vk1ejG6kOHN3XuMvn_-9O38a3N18-Xy_Oyq6QWRbSMd0QCqF4NS0JFBinbQgnXAuRmlcM6MIKlSlGkjRTfWmgFj2MiVoUx1_Bh9PHA3S7eGoa-nJhfsJvm1S3sbnbdPO7Of7I-4tVIxxWlbAe_vACn-XiAXu_a5r99yM8QlW2qEEFwLSaqUH6R9ijknGB_WUGL_mmSvL-z_JtWpd48vfJi5d6UKxEGwi6FAyr_CsoNkJ3ChTP94UhvWMEI1McyQplZUy_8AMNWeJg</recordid><startdate>20170901</startdate><enddate>20170901</enddate><creator>Dai, Wenjie</creator><creator>Ye, Ling</creator><creator>Liu, Aizhong</creator><creator>Wen, Shi Wu</creator><creator>Deng, Jing</creator><creator>Wu, Xin</creator><creator>Lai, Zhiwei</creator><general>The Authors. Published by Wolters Kluwer Health, Inc. All rights reserved</general><general>Wolters Kluwer Health</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20170901</creationdate><title>Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: A meta-analysis</title><author>Dai, Wenjie ; Ye, Ling ; Liu, Aizhong ; Wen, Shi Wu ; Deng, Jing ; Wu, Xin ; Lai, Zhiwei</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4058-5a07ee6c4d66eb0d548d742be339f54aa9fe5166127954bff549e992f369126b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Diabetes Mellitus, Type 2 - complications</topic><topic>Disease Management</topic><topic>Early Diagnosis</topic><topic>Humans</topic><topic>Needs Assessment</topic><topic>Non-alcoholic Fatty Liver Disease - diagnosis</topic><topic>Non-alcoholic Fatty Liver Disease - epidemiology</topic><topic>Non-alcoholic Fatty Liver Disease - therapy</topic><topic>Prevalence</topic><topic>Systematic Review and Meta-Analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dai, Wenjie</creatorcontrib><creatorcontrib>Ye, Ling</creatorcontrib><creatorcontrib>Liu, Aizhong</creatorcontrib><creatorcontrib>Wen, Shi Wu</creatorcontrib><creatorcontrib>Deng, Jing</creatorcontrib><creatorcontrib>Wu, Xin</creatorcontrib><creatorcontrib>Lai, Zhiwei</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Medicine (Baltimore)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dai, Wenjie</au><au>Ye, Ling</au><au>Liu, Aizhong</au><au>Wen, Shi Wu</au><au>Deng, Jing</au><au>Wu, Xin</au><au>Lai, Zhiwei</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: A meta-analysis</atitle><jtitle>Medicine (Baltimore)</jtitle><addtitle>Medicine (Baltimore)</addtitle><date>2017-09-01</date><risdate>2017</risdate><volume>96</volume><issue>39</issue><spage>e8179</spage><epage>e8179</epage><pages>e8179-e8179</pages><issn>0025-7974</issn><eissn>1536-5964</eissn><abstract>Nonalcoholic fatty liver disease (NAFLD) is emerging as a public health issue worldwide and is highly prevalent in patients with type 2 diabetes mellitus (T2DM). However, there was a great disparity across studies in the estimated prevalence of NAFLD in T2DM patients. This meta-analysis, therefore, aimed to estimate the pooled prevalence of NAFLD in T2DM patients. Electronic databases of PubMed, Web of Science, Embase, Chinese National Knowledge Infrastructure, and Wanfang were searched using MeSH terms to identify relevant studies. Eligibility assessment and data extraction were conducted independently by 2 investigators and a meta-analysis was performed to synthesize the data. Heterogeneity was evaluated using the Cochran Q test and quantified using the I statistic. Publication bias was assessed using both the Begg and Egger tests. Subgroup analyses were performed to identify the possible sources of heterogeneity. Twenty-four studies involving 35,599 T2DM patients were included in this meta-analysis, of which 20,264 were identified with NAFLD. A high degree of heterogeneity (I = 99.0%, P &lt; .001) was observed among the eligible studies, with the reported prevalence ranging from 29.6% to 87.1%. The pooled prevalence of NAFLD in T2DM patients, by a random-effects model, was 59.67% (95% confidence interval: 54.31-64.92%). Sensitivity was low and both the Begg test and Egger test showed low possibility of publication bias. Subgroup analyses indicated that the prevalence of NAFLD in T2DM patients differed by gender, obesity, hypertension, dyslipidemia, coronary heart disease, and chronic kidney disease. The high pooled prevalence of NAFLD in T2DM patients found in this study significantly underscores the need for early assessment of NAFLD and the importance of strengthening the management of NAFLD in T2DM patients.</abstract><cop>United States</cop><pub>The Authors. Published by Wolters Kluwer Health, Inc. All rights reserved</pub><pmid>28953675</pmid><doi>10.1097/MD.0000000000008179</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0025-7974
ispartof Medicine (Baltimore), 2017-09, Vol.96 (39), p.e8179-e8179
issn 0025-7974
1536-5964
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5626318
source MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Wolters Kluwer Open Health; IngentaConnect Free/Open Access Journals; PubMed Central; Alma/SFX Local Collection
subjects Diabetes Mellitus, Type 2 - complications
Disease Management
Early Diagnosis
Humans
Needs Assessment
Non-alcoholic Fatty Liver Disease - diagnosis
Non-alcoholic Fatty Liver Disease - epidemiology
Non-alcoholic Fatty Liver Disease - therapy
Prevalence
Systematic Review and Meta-Analysis
title Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: A meta-analysis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T19%3A41%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prevalence%20of%20nonalcoholic%20fatty%20liver%20disease%20in%20patients%20with%20type%202%20diabetes%20mellitus:%20A%20meta-analysis&rft.jtitle=Medicine%20(Baltimore)&rft.au=Dai,%20Wenjie&rft.date=2017-09-01&rft.volume=96&rft.issue=39&rft.spage=e8179&rft.epage=e8179&rft.pages=e8179-e8179&rft.issn=0025-7974&rft.eissn=1536-5964&rft_id=info:doi/10.1097/MD.0000000000008179&rft_dat=%3Cproquest_pubme%3E1944437450%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1944437450&rft_id=info:pmid/28953675&rfr_iscdi=true